First- and Second-Generation Antipsychotics for Children and Young Adults
Summary of Adverse Effects of Second-Generation Antipsychotics
Current evidence indicates that there are differences between individual second-generation antipsychotics (SGAs) in the risk and severity of key adverse effects. However, in the absence of direct comparisons, subjective interpretations of relative risk and severity can be made using data from placebo comparisons.
In the current evidence base of direct comparisons of SGAs, statistically significant differences are noted in the rate or severity of dyslipidemia and in adverse changes in weight and body composition. Among the SGAs, olanzapine exhibits the most severe adverse effects on weight and blood lipids.
There is limited evidence of no statistically significant difference between SGAs in other direct comparisons of adverse effects (insulin and glucose control, extrapyramidal symptoms, and sedative effects).
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.